AI Is Ready: How to Use Predictive Intelligence to De-Risk Biotech Decisions Today

Session details:

What if you could predict the outcome of your next trial? What if you could know, before starting, whether your candidate will hit its endpoints?  For years, AI in drug discovery has been discussed in future tense: promises of what it could one day deliver. Or in some cases, AI is avoided altogether due to the need for longer-term collaborative commitments that require AI integration into existing development processes. In this session, you’ll see how AI is already enabling biotech and investors to ask - and answer - the questions that are required for all investments. 

Rather than abstract promises, today’s predictive AI tools are producing objective, actionable insights in weeks, not years; empowering leaders to make go/no-go calls faster, prioritize pipelines with confidence, and design trials with a higher probability of success. If financial firms can rely on AI to direct capital with precision, why shouldn’t drug developers have the same level of intelligence—a FICO score or Carfax for their assets?

Attendees will leave with:

A clear-eyed view of how AI is already reducing risk in biotech decision-making
Examples of how predictive intelligence strengthens investor confidence, portfolio management, and trial design
A framework for integrating AI-based readiness tools alongside traditional R&D approaches